IFPMA Geneva Pharma Forum: Access to antiretrovirals in developing countries: towards a new landscape?
Read moreVaccine supply data from 157 countries shows that global vaccination levels remain low; while policy measures that directly impact patients are linked to higher levels of Influenza Vaccination. Two studies being published this week in peer-reviewed journals look at global vaccination policies and use global vaccination provision data that had not been previously available. The...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) welcomes the decision taken at the Asia-Pacific Economic Cooperation CEO Summit to endorse “The Mexico City Principles for Voluntary Codes of Business Ethics in the Biopharmaceutical Sector”, often referred to as the “Mexico City Principles”. These principles are fully aligned with the IFPMA’s global Code of...
Read moreIFPMA, the body representing the global research-based pharmaceutical industry, welcomes the creation of WIPO Re:Search, a new voluntary database for sharing intellectual property for R&D on medicines and vaccines for tuberculosis, malaria and neglected tropical diseases. WIPO Re:Search was launched today in Geneva by the World Intellectual Property Organisation (WIPO), and was followed by a...
Read moreA report “Evidence on Access to Essential Medicines for the Treatment of HIV/AIDS 1 The report funded by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) provides insights into what measures can substantially increase ART coverage levels to over 80%. The report studied seven countries from across the globe (Botswana, Brazil, India, Mexico, Rwanda,...
Read moreTo coincide with the United Nations High-Level Meeting on NCDs, the research-based pharmaceutical industry today outlined the steps it is taking to address the rise of NCDs in the developing world. Building on its Framework for Action released earlier this year, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) revealed the findings of the...
Read moreby Dr. Patrizia Carlevaro, Head of International Aid Unit, Eli Lilly and Company, Geneva IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Patrizia Carlevaro, Head of International Aid Unit, Eli Lilly and Company, Geneva IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Brendan Barnes, Director, Multilateral Issues & Health Policy, EFPIA, Brussels IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Brendan Barnes, Director, Multilateral Issues & Health Policy, EFPIA, Brussels IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Brendan Barnes, Director, Multilateral Issues & Health Policy, EFPIA, Brussels IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Alan Oxley, Chairman APEC Centre, RMIT University, Melbourne IFPMA Geneva Pharma Forum on 24 November 2009
Read more